Share on StockTwits
 

Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) posted its quarterly earnings results on Thursday. The company reported $1.42 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.26 by $0.16, Stock Ratings News reports. The company had revenue of $5.40 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter in the prior year, the company posted $1.32 earnings per share. The company’s quarterly revenue was up 2.9% on a year-over-year basis.

A number of research firms have recently commented on TEVA. Analysts at TheStreet upgraded shares of Teva Pharmaceutical Industries Ltd from a “hold” rating to a “buy” rating in a research note to investors on Wednesday, January 29th. On the ratings front, analysts at CRT Capital raised their price target on shares of Teva Pharmaceutical Industries Ltd from $50.00 to $55.00 in a research note to investors on Wednesday, January 29th. They now have a “buy” rating on the stock. Finally, analysts at Citigroup Inc. raised their price target on shares of Teva Pharmaceutical Industries Ltd from $47.00 to $50.00 in a research note to investors on Tuesday, January 28th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the company’s stock. Teva Pharmaceutical Industries Ltd presently has an average rating of “Hold” and a consensus price target of $45.15.

Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) is a global pharmaceutical and drug company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.